Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Introduction APC and the Wnt pathway K‐ras initiated pathways The TGF‐β pathway P53 and its functional regulation and dysregulation in colorectal cancer The ubiquitin‐proteasome system (UPS) The ubiquitin‐proteasome system in apoptosis and the cell cycle Proteasome inhibition in colorectal carcinoma Cox‐2 in colorectal cancer Cox‐2 and lipid metabolism in colorectal cancer Cox‐independent anti‐carcinogenic effects of Cox inhibitors Combined Cox and proteasome inhibition in colorectal cancer Pathways of the molecular pathogenesis of colorectal carcinoma have been extensively studied and molecular lesions during the development of the disease have been revealed. High up in the list of colorectal cancer lesions are APC (adenomatous polyposis coli), K‐ras, Smad4 (or DPC4‐deleted in pancreatic cancer 4) and p53 genes. All these molecules are part of important pathways for the regulation of cell proliferation and apoptosis and as a result perturbation of these processes lead to carcinogenesis. The ubiquitin–proteasome system (UPS) is comprised of a multi‐unit cellular protease system that regulates several dozens of cell proteins after their ligation with the protein ubiquitin. Given that among these proteins are regulators of the cell cycle, apoptosis, angiogenesis, adhesion and cell signalling, this system plays a significant role in cell fate and carcinogenesis. UPS inhibition has been found to be a pre‐requisite for apoptosis and is already clinically exploited with the proteasome inhibitor bortezomib in multiple myeloma. Cyclooxygenase‐2 (Cox‐2) is the inducible form of the enzyme that metabolizes the lipid arachidonic acid to prostaglandin H 2, the first step of prostaglandins production. This enzyme is up‐regulated in colorectal cancer and in several other cancers. Inhibition of Cox‐2 by aspirin and other non‐steroidal anti‐inflammatory drugs (NSAIDs) has been found to inhibit proliferation of colorectal cancer cells and in epidemiologic studies has been shown to reduce colon polyp formation in genetically predisposed populations and in the general population. NSAIDs have also Cox‐independent anti‐proliferative effects. Targeted therapies, the result of increasingly understanding carcinogenesis in the molecular level, have entered the field of anti‐neoplastic treatment and are used by themselves and in combination with chemotherapy drugs. Combinations of targeted drugs have started also to be investigated. This article reviews the molecular pathogenesis of colorectal cancer, the roles of UPS and Cox‐2 in it and puts forward a rational for their combined inhibition in colorectal cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I., & Chen, Z. J. (2001) · Nature · doi:10.1038/35085597 · Cited by 2,125
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“After Wnt ligation Frizzled activates the protein dishevelled, which in cooperation with GSK3 binding protein (GBP) inhibits the kinase GSK3 (glycogen synthase kinase-3 ) [14, 15] (Fig.”
BackgroundThe β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate
Brash, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23679 · Cited by 1,335 · cited 1×
“Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd HETE (15-S-Hydroxy-eicosa-tetraenoic acid) [232].”
BackgroundThe MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“Other transcription factors activated by ERKs include elk1 and c-myc [58].”
BackgroundUbiquitin signalling in the NF-κB pathway
Chen, Z. J. (2005) · Nature Cell Biology · doi:10.1038/ncb0805-758 · Cited by 1,184 · cited 1×
“NF- B is in reality a family of related proteins that include REL-A (p65), REL-B, c-REL, p50 and p52, which bind their cognate DNA sequences as dimers [141].”
BackgroundLehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 12×
“Nuclear receptor family transcription factor PPAR / lies Cox-2 β-catenin/ TCF4 NF-κB ERK1/ 2 p38/MAPK NFAT”
BackgroundInfluentialAPC, Signal transduction and genetic instability in colorectal cancer
Fodde, R., Smits, R., & Clevers, H. (2001) · Nature Reviews Cancer · doi:10.1038/35094067 · Cited by 937 · cited 2×
“Normal colon epithelial cells, in their way to malignancy, pass through a sequence of stages, which include the formation of aberrant crypt foci (ACF), subsequently the formation of adenoma and finally carcinoma [1].”
BackgroundKirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 1×
“The oncogene K-ras has activating mutations, especially in codon 12, in about 40% to 50% of colorectal carcinomas [55, 56].”
Background
Cited by
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Mutations of p53 associated with pancreatic cancer and therapeutic implications
Voutsadakis, I. A. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.3.315 · Cited by 75
Self-citationVoutsadakis, I. A. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100746 · Cited by 14
Self-citation
Metadata
- Authors
- Voutsadakis, I. A.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2007-03
- Volume
- 11
- Issue
- 2
- Pages
- 252-285
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2120558703
- Cited by
- 74
- References
- 15
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2. https://app.cochat.ai/papers/10.1111/j.1582-4934.2007.00032.x
- The paper
- Voutsadakis, I. A. (2007). Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2007.00032.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.